Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:ceo |
gptkb:Li_Wei
|
| gptkbp:certification |
GMP certified
|
| gptkbp:clinical_trial |
Conducts regularly
|
| gptkbp:employees |
Over 1000
|
| gptkbp:focus |
Innovative drug development
|
| gptkbp:founded |
gptkb:1995
|
| gptkbp:headquarters |
gptkb:China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zhongjin Pharmaceutical
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
Global
|
| gptkbp:partnerships |
Various international firms
|
| gptkbp:products |
Generic drugs
|
| gptkbp:research_areas |
Multiple in China
|
| gptkbp:revenue |
Approximately $500 million
|
| gptkbp:services |
gptkb:Research_Institute
|
| gptkbp:subsidiary |
Zhongjin Biotech
|
| gptkbp:website |
www.zhongjinpharma.com
|
| gptkbp:bfsParent |
gptkb:Ali_Health
|
| gptkbp:bfsLayer |
4
|